Valneva (NASDAQ:VALN) Trading 6.1% Higher

Valneva SE (NASDAQ:VALN)’s stock price traded up 6.1% during mid-day trading on Thursday . The stock traded as high as $8.22 and last traded at $8.22. 1,859 shares were traded during mid-day trading, a decline of 80% from the average session volume of 9,146 shares. The stock had previously closed at $7.75.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Valneva in a research report on Thursday, March 21st. Guggenheim cut their price objective on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd.

Valneva Stock Up 4.9 %

The company’s fifty day moving average is $7.68 and its 200-day moving average is $9.65. The company has a market capitalization of $564.71 million, a PE ratio of -5.20 and a beta of 2.25. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.37 and a current ratio of 1.65.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). The business had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. As a group, analysts predict that Valneva SE will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Several hedge funds have recently modified their holdings of VALN. UBS Group AG purchased a new position in shares of Valneva in the second quarter worth $31,000. Jane Street Group LLC boosted its stake in Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after buying an additional 7,664 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in Valneva during the first quarter valued at approximately $858,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.